K. Verhamme

First name

K.

Last name

Verhamme

Raventós, B., Català, M., Du, M., Guo, Y., Black, A., Inberg, G., et al. (2023). IncidencePrevalence: An R package to calculate population-level incidence rates and prevalence using the OMOP common data model. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5717

View

Li, X., Burn, E., Duarte-Salles, T., Yin, C., Reich, C., Delmestri, A., et al. (2022). Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. Bmj, 379, e071594. http://doi.org/10.1136/bmj-2022-071594

View

Burn, E., Li, X., Kostka, K., Stewart, H. M., Reich, C., Seager, S., et al. (2022). Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiol Drug Saf, 31, 495-510. http://doi.org/10.1002/pds.5419

View

Li, X., Ostropolets, A., Makadia, R., Shoaibi, A., Rao, A., Sena, A. G., et al. (2021). Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. http://doi.org/10.1136/bmj.n1435

View